| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
VBI Vaccines Inc (NASDAQ: VBIV)
VBIV Technical Analysis
5
| As on 9th Jun 2023 VBIV STOCK Price closed @ 2.76 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.17 & Strong Buy for SHORT-TERM with Stoploss of 1.79 we also expect STOCK to react on Following IMPORTANT LEVELS. |
VBIVSTOCK Price
| Open | 2.81 | Change | Price | % |
| High | 2.84 | 1 Day | -0.02 | -0.72 |
| Low | 2.72 | 1 Week | -0.21 | -7.07 |
| Close | 2.76 | 1 Month | 0.27 | 10.84 |
| Volume | 35300 | 1 Year | 0.39 | 16.46 |
| 52 Week High 3.64 | 52 Week Low 0.12 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| VBIV Daily Charts |
VBIV Intraday Charts |
Whats New @ Bazaartrend |
VBIV Free Analysis |
|
|
VBIV Important Levels Intraday
| RESISTANCE | 2.99 |
| RESISTANCE | 2.92 |
| RESISTANCE | 2.87 |
| RESISTANCE | 2.83 |
| SUPPORT | 2.69 |
| SUPPORT | 2.65 |
| SUPPORT | 2.60 |
| SUPPORT | 2.53 |
VBIV Forecast May 2024
| 4th UP Forecast | 4.34 |
| 3rd UP Forecast | 3.83 |
| 2nd UP Forecast | 3.52 |
| 1st UP Forecast | 3.21 |
| 1st DOWN Forecast | 2.31 |
| 2nd DOWN Forecast | 2 |
| 3rd DOWN Forecast | 1.69 |
| 4th DOWN Forecast | 1.18 |
VBIV Weekly Forecast
| 4th UP Forecast | 3.42 |
| 3rd UP Forecast | 3.21 |
| 2nd UP Forecast | 3.08 |
| 1st UP Forecast | 2.95 |
| 1st DOWN Forecast | 2.57 |
| 2nd DOWN Forecast | 2.44 |
| 3rd DOWN Forecast | 2.31 |
| 4th DOWN Forecast | 2.10 |
VBIV Forecast2024
| 4th UP Forecast | 11.14 |
| 3rd UP Forecast | 8.45 |
| 2nd UP Forecast | 6.79 |
| 1st UP Forecast | 5.13 |
| 1st DOWN Forecast | 0.39 |
| 2nd DOWN Forecast | -1.27 |
| 3rd DOWN Forecast | -2.93 |
| 4th DOWN Forecast | -5.62 |
VBI Vaccines Inc ( NASDAQ USA Symbol : VBIV )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VBIV Business Profile
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts. Address: 222 Third Street, Cambridge, MA, United States, 02142
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service